RE:Sobering statistics in oncology trials it has a couple things going for it which will increase the odds of success greatly. They are using Docetaxel which already works and is approved. It doesn't even have to be more effective than Docetaxel alone. If it's only just as effective but at a lower dose meaning less side effects then it will still be approved. The only wild card is over accumulation in healthy cells expressing sortilin.
palinc2000 wrote: Very low [3.8%] success rate.....I fail to see any known hard facts in our own Phase 1 apart that it is still ongoing and dosing levels have increased but to unknown levels.What dont I get? Would love to get excited but I see nothing except hope
https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845